Lv1
50 积分 2025-07-07 加入
Liver, ageing and disease
21天前
已完结
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study
1个月前
已完结
Preoperative predictors of early recurrence after resection for hepatocellular carcinoma
4个月前
已完结
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection
6个月前
已完结
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection
6个月前
已完结
Precision surgery for hepatocellular carcinoma
6个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
6个月前
已完结
Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors
6个月前
已完结
Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis
6个月前
已完结
Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection
6个月前
已完结
皖公网安备34019202002308
